CTSO Quote, Financials, Valuation and Earnings

Exact Sciences has a net margin of -27.1% compared to CytoSorbents's net margin of -5.4%. CytoSorbents's return on equity of -103.21% beat Exact Sciences's return on equity of -6.77%.

CytoSorbents has a consensus price target of --, signalling upside risk potential of 459.79%. On the other hand Exact Sciences has an analysts' consensus of $71.86 which suggests that it could grow by 23.66%. Given that CytoSorbents has higher upside potential than Exact Sciences, analysts believe CytoSorbents is more attractive than Exact Sciences.

CytoSorbents has a beta of 0.568, which suggesting that the stock is 43.192% less volatile than S&P 500. In comparison Exact Sciences has a beta of 1.237, suggesting its more volatile than the S&P 500 by 23.719%.

CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

CytoSorbents quarterly revenues are $8.6M, which are smaller than Exact Sciences quarterly revenues of $708.7M. CytoSorbents's net income of -$2.3M is higher than Exact Sciences's net income of -$38.2M. Notably, CytoSorbents's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.39x versus 3.95x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Illumina has a net margin of -27.1% compared to CytoSorbents's net margin of 65.28%. CytoSorbents's return on equity of -103.21% beat Illumina's return on equity of -37.83%.

CytoSorbents has a consensus price target of --, signalling upside risk potential of 459.79%. On the other hand Illumina has an analysts' consensus of $148.36 which suggests that it could grow by 20.94%. Given that CytoSorbents has higher upside potential than Illumina, analysts believe CytoSorbents is more attractive than Illumina.

CytoSorbents has a beta of 0.568, which suggesting that the stock is 43.192% less volatile than S&P 500. In comparison Illumina has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.544%.

CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend.

CytoSorbents quarterly revenues are $8.6M, which are smaller than Illumina quarterly revenues of $1.1B. CytoSorbents's net income of -$2.3M is lower than Illumina's net income of $705M. Notably, CytoSorbents's price-to-earnings ratio is -- while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.39x versus 4.90x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

Progyny has a net margin of -27.1% compared to CytoSorbents's net margin of 3.64%. CytoSorbents's return on equity of -103.21% beat Progyny's return on equity of 11.31%.

CytoSorbents has a consensus price target of --, signalling upside risk potential of 459.79%. On the other hand Progyny has an analysts' consensus of $30.22 which suggests that it could grow by 29.78%. Given that CytoSorbents has higher upside potential than Progyny, analysts believe CytoSorbents is more attractive than Progyny.

CytoSorbents has a beta of 0.568, which suggesting that the stock is 43.192% less volatile than S&P 500. In comparison Progyny has a beta of 1.350, suggesting its more volatile than the S&P 500 by 34.952%.

CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend.

CytoSorbents quarterly revenues are $8.6M, which are smaller than Progyny quarterly revenues of $286.6M. CytoSorbents's net income of -$2.3M is lower than Progyny's net income of $10.4M. Notably, CytoSorbents's price-to-earnings ratio is -- while Progyny's PE ratio is 25.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.39x versus 1.26x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of -27.1% compared to CytoSorbents's net margin of -14.42%. CytoSorbents's return on equity of -103.21% beat Star Equity Holdings's return on equity of -10.13%.

CytoSorbents has a consensus price target of --, signalling upside risk potential of 459.79%. On the other hand Star Equity Holdings has an analysts' consensus of -- which suggests that it could grow by 380.77%. Given that CytoSorbents has higher upside potential than Star Equity Holdings, analysts believe CytoSorbents is more attractive than Star Equity Holdings.

CytoSorbents has a beta of 0.568, which suggesting that the stock is 43.192% less volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.080, suggesting its less volatile than the S&P 500 by 91.951%.

CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Star Equity Holdings pays out 7.62% of its earnings as a dividend. Star Equity Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CytoSorbents quarterly revenues are $8.6M, which are smaller than Star Equity Holdings quarterly revenues of $13.7M. CytoSorbents's net income of -$2.3M is lower than Star Equity Holdings's net income of -$2M. Notably, CytoSorbents's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.39x versus 0.13x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.